Cardiovascular disease is the leading cause of mortality and morbidity throughout the world,
accounting for 16.7 million deaths each year. The underlying pathological process for the …

Coronary heart disease (CHD) is the main cause of death and morbidity in the world. There
is a strong evidence that the atherosclerotic process begins in childhood and that …

Background Information on the real‐world use of proprotein convertase subtilisin kexin 9
inhibitors (PCKS9is) in familial hypercholesterolemia are limited. We evaluated the pattern …

Background: Proprotein convertase subtilisin kexin type 9 inhibitors (PCSK9i) lower LDL-
cholesterol and slow atherosclerosis preventing cardiovascular events. While it is known …

Aim Loss of immunosuppressive response supports inflammation during atherosclerosis.
We tested whether adoptive cell therapy (ACT) with Tregulatory cells (Tregs), engineered to …

Activation of T cells relies on the availability of intracellular cholesterol for an effective
response after stimulation. We investigated the contribution of cholesterol derived from …

Background Familial hypercholesterolemia (FH) may arise from deleterious monogenic
variants in FH‐causing genes as well as from a polygenic cause. We evaluated the …

Background and aims Nonalcoholic fatty liver disease (NAFLD) may be crucial in subjects
with familial hypercholesterolemia (FH). We aimed to evaluate the effect of the inhibitors of …

Aims Familial hypercholesterolemia (FH) is the most common genetic disorder of lipid
metabolism. The gold standard for FH diagnosis is genetic testing, available, however, only …

Background Familial hypercholesterolemia (FH) is characterized by increased
cardiovascular risk; despite-high intensity statins, only few patients with FH achieve the …